Skip to content

Why This Seemingly ‘Great Deal’ Pharma Stock Is Contraindicated

With a massive cash balance (and no debt), rapidly growing revenue and earnings, and a well-stocked pipeline, the pharma stock that’s the focus of today’s article, trading at just six times earnings, would appear on the surface to be a great pick for value investors. The author cautions, however, that “there’s a solid bearish argument that is scaring investors away from the stock” – and he examines the validity of the various claims underlying this argument. For more, CLICK HERE.